An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-Infected patients by use of the Abbott RealTime HCV RNA assay

Journal of Clinical Microbiology

Volumn 53, Issue 4, 2015, Pages 1264-1269

  Sarrazin, Christoph ^a   Dierynck, Inge ^b   Cloherty, Gavin ^c   Ghys, Anne ^b   Janssen, Katrien ^b   Luo, Donghan ^d   Witek, James ^d   Buti, Maria ^e   Picchio, Gaston ^d   De Meyer, Sandra ^b  

^a GOETHE UNIVERSITY   (Germany)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c Abbott Molecular Inc   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ARTICLE; BLOOD ANALYSIS; BLOOD ANALYSIS EQUIPMENT; BLOOD SAMPLING; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RETROSPECTIVE STUDY; RNA ANALYSIS; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG MONITORING; EVALUATION STUDY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PROCEDURES; VIROLOGY; VIRUS LOAD;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGOPEPTIDES; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84925238090     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03030-14     Document Type: Article

References (26)

1. Chevaliez S, Rodriguez C, Pawlotsky JM. 2012. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303-1313. http://dx.doi.org/10.1053/j.gastro.2012.02.027.
2. Peiffer KH, Sarrazin C. 2013. The importance of HCV RNA measurement for tailoring treatment duration. Dig Liver Dis 45(Suppl 5):S323-S331. http://dx.doi.org/10.1016/j.dld.2013.07.007.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team. 2011. Telaprevir for previously untreated chronic hepatitisCvirus infection.NEngl JMed 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
4. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, ILLUMINATE Study Team. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection.NEngl J Med 365:1014-1024. http://dx.doi.org/10.1056/NEJMoa1014463. (Erratum, N Engl J Med 365:1551.)
5. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, REALIZE Study Team. 2011. Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417-2428. http://dx.doi.org/10.1056/NEJMoa1013086.
6. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217. http://dx.doi.org/10.1056/NEJMoa1009482.
8. European Medicines Agency. 2011. INCIVO (telaprevir) tablets. Summary of product characteristics October 2011. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002313/WC500115529.pdf.
9. Vertex Pharmaceuticals, Inc. 2012. Incivek (telaprevir) film coated tablets for oral use: highlights of prescribing information. Vertex Pharmaceuticals, Inc., Cambridge, MA. http://pi.vrtx.com/files/uspi-telaprevir.pdf.
10. Harrington PR, Zeng W, Naeger LK. 2012. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 55:1048-1057. http://dx.doi.org/10.1002/hep.24791.
11. Colucci G, Ferguson J, Harkleroad C, Lee S, Romo D, Soviero S, Thompson J, Velez M, Wang A, Miyahara Y, Young S, Sarrazin C. 2007. Improved COBAS TaqMan hepatitis C virus test (version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 45:3595-3600. http://dx.doi.org/10.1128/JCM.01320-07.
12. Zitzer H, Heilek G, Truchon K, Susser S, Vermehren J, Sizmann D, Cobb B, Sarrazin C. 2013. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dualprobe assay design. J Clin Microbiol 51:571-577. http://dx.doi.org/10.1128/JCM.01784-12.
13. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, Bertuzis R, Schneider G, Sarrazin C. 2011. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 52:133-137. http://dx.doi.org/10.1016/j.jcv.2011.07.007.
14. Kessler HH, Hübner M, Konrad PM, Stelzl E, Stübler MM, Baser MH, Santner BI. 2013. Genotype impact on HCV RNA levels determined with the Versant HCV RNA 1.0 assay (kPCR). J Clin Virol 58:522-527. http://dx.doi.org/10.1016/j.jcv.2013.09.005.
15. Paba P, Fabeni L, Perno CF, Ciotti M. 2012. Performance evaluation of the Artus hepatitisCQS-RGQ assay. J Virol Methods 179:77-80. http://dx.doi.org/10.1016/j.jviromet.2011.09.024.
16. Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Picchio D, Sarrazin C. 2014. Hepatitis C virus RNA quantification with different assays: implications for protease inhibitor-based response guided therapy. Antivir Ther 19:559-567. http://dx.doi.org/10.3851/IMP2760.
17. Cloherty G, Cohen D, Herman C, Bernstein B, Pawlotsky J. 2012. HCV RNA assay sensitivity impacts the management of patients taking DAA. Hepatology 56(Suppl 4):560A. http://onlinelibrary.wiley.com/doi/10.1002/hep.26040/pdf.
18. Braun P, Wiesmann F, Berger A, Kaiser R, Naeth G, Ehret R, Knechten H. 2013. Comparison of viral load assays for the quantification of HCV genotypes 1-4 in the setting of low viremic samples, abstr 465. Fifth Eur Congr Virol, Lyon, France, 11 to 14 September 2013.
19. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS, Hézode C, Rizzetto M, Paraná R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J. 2014. Telaprevir twice daily is noninferior to telaprevir every 8 hrs for patients with chronic hepatitis C. Gastroenterology 146:744-753. http://dx.doi.org/10.1053/j.gastro.2013.11.047.
20. Roche Molecular Systems, Inc. 2010. COBAS AmpliPrep/COBAS TaqMan HCV test, v2.0, for use with the High Pure system, package insert. Roche Molecular Systems, Inc., Branchburg, NJ.
21. Abbott Molecular, Inc. 2011. Abbott RealTime HCV package insert. Abbott Molecular, Inc., Des Plaines, IL.
22. Vermehren J, Kau A, Gärtner BC, Göbel R, Zeuzem S, Sarrazin C. 2008. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46:3880-3891. http://dx.doi.org/10.1128/JCM.00755-08.
23. Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J. 2013. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based therapy: a comparison of two real-time PCR assays. Antiviral Res 99:119-124. http://dx.doi.org/10.1016/j.antiviral.2013.05.002.
24. Maasoumy B, Cobb B, Bremer B, Luk K, Halfon P, Aslam S, Manns MP, Cornberg M, Wedemeyer H. 2014. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther 39:85-92. http://dx.doi.org/10.1111/apt.12544.
25. Braun P, Wiesmann F, Berger A, Kaiser R, Naeth G, Ehret R, Knechten H. 2013. Comparative analysis of five viral load assays in quantifying low viremic HCV samples in the range of clinical decision points. Antivir Ther 18(Suppl 1):A93. http://www.intmedpress.com/serveFile.cfm?sUID=11ce9800-f660-437d-85e5-5a79b7f7f1f3.
26. Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C. 2014. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol 60:913-919. http://dx.doi.org/10.1016/j.jhep.2014.01.002.